The Platform
A new way to make hard-to-dissolve drugs work
More than 65% of active pharmaceutical ingredients (APIs) suffer from poor aqueous solubility. The usual fix is loading the formulation with excipients, which can cause adverse reactions and limits delivery to solid, oral pills. RapiDrugs removes the excipients entirely and conjugates the API directly with a biocompatible Bio-organic Moiety (BOM), producing a reformulated API (rAPI) that is soluble, liquid, and open to new delivery modes.
Why it works
A more water-loving molecule
Conjugating the API with a BOM makes the resulting molecule far more polar, so it binds water more readily. That single change is what unlocks the solubility gains across every drug we've tested. And because excipients are removed rather than added, the resulting rAPI is simpler to manufacture than a traditional formulation.
Enhanced solubility
Up to a 600× increase
Across our pilot NSAID molecules, rAPIs show a 100 to 1,000 fold increase in aqueous solubility compared to the parent API. For diclofenac, the two candidate BOM conjugates lifted solubility 600× and 325× over the unmodified drug.
Faster dissolution
Minutes, not hours
Where the parent API can take close to two hours to fully dissolve, our rAPIs get there in around 20 minutes, a direct route to a quicker onset of action. That also opens the door to delivery formats a poorly soluble drug can't support today, like oral solutions and fast-acting injectables.
Improved in-vivo performance
Backed by real pharmacokinetic data
In-vivo studies show our rAPIs reach the bloodstream faster and at higher concentrations than the parent drug, consistent with a faster, more predictable effect in the body. That's the kind of result that matters most to a licensing partner, since it's measured the same way regulators already evaluate a drug.
